Department of Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Liver Int. 2022 Oct;42(10):2167-2174. doi: 10.1111/liv.15349. Epub 2022 Jul 1.
In vitro fertilization-embryo transfer (IVF-ET) may increase the risk of mother-to-child transmission (MTCT) of hepatitis B virus (HBV). The purpose of this study was to investigate the impact and safety of IVF-ET on MTCT in women with chronic HBV infection (CHB).
The data of 298 women who got pregnant by IVF-ET and their 375 children were collected retrospectively. Mothers were divided into the CHB group (n = 224) and the control group (HBsAg negative, n = 74). After birth, newborns were routinely vaccinated with the hepatitis B vaccine, and infants in the CHB group were injected with hepatitis B immunoglobulin within 2 h after birth. Demographic information, clinical data and laboratory test results were collected. The primary outcome measures were the MTCT rate of HBV, and the secondary outcome measures were the safety of the mother and infant.
There was no case of HBV MTCT in all 282 newborns born in the CHB group and 93 neonates born in the control group. Of the two groups, the birth weight (3056.74 ± 601.65 vs. 2926.24 ± 704.86, P = .083), length (49.22 ± 1.97 vs. 48.74 ± 3.09, P = .167), 5-min Apgar score (9.97 ± 0.21 vs. 9.90 ± 0.51, P = .212), days of pregnancy (265.70 ± 12.73 vs. 262.02 ± 17.50, P = .064) and neonatal malformation rate (0.71% vs. 0, P = 1.000) were similar. Two cases of neonatal malformation occurred in the CHB group. The incidences of pregnancy and childbirth complications were similar between the two groups.
IVF-ET does not increase the risk of MTCT in women with chronic HBV infection, and it is safe for mothers and infants.
体外受精-胚胎移植（IVF-ET）可能会增加乙型肝炎病毒（HBV）母婴传播（MTCT）的风险。本研究旨在探讨 IVF-ET 对慢性乙型肝炎病毒感染（CHB）妇女 MTCT 的影响和安全性。
回顾性收集了 298 名通过 IVF-ET 受孕的妇女及其 375 名子女的数据。母亲分为 CHB 组（n=224）和对照组（HBsAg 阴性，n=74）。出生后，新生儿常规接种乙肝疫苗，CHB 组婴儿在出生后 2 小时内注射乙肝免疫球蛋白。收集人口统计学信息、临床资料和实验室检查结果。主要结局指标为 HBV 的 MTCT 率，次要结局指标为母婴安全性。
CHB 组 282 名新生儿和对照组 93 名新生儿均未发生 HBV MTCT。两组出生体重（3056.74±601.65 vs. 2926.24±704.86，P=0.083）、身长（49.22±1.97 vs. 48.74±3.09，P=0.167）、5 分钟 Apgar 评分（9.97±0.21 vs. 9.90±0.51，P=0.212）、妊娠天数（265.70±12.73 vs. 262.02±17.50，P=0.064）和新生儿畸形率（0.71% vs. 0，P=1.000）相似。CHB 组有 2 例新生儿畸形。两组妊娠和分娩并发症的发生率相似。
IVF-ET 不会增加慢性 HBV 感染妇女 MTCT 的风险，对母婴安全。
